13F Holdings
中文EN

ORMP ORAMED PHARMACEUTICALS INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1176309 · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY435.3%
TTM EPS YoY412.5%
Revenue 3-yr CAGR-11.9%
Net income 3-yr CAGR—

Margins

Gross margin0.7%
Operating margin-754.4%
Net margin3,202.5%
FCF margin-457.7%
EBITDA margin-748.4%

Returns

ROE37.0%
ROA33.2%
ROIC (approx.)-10.4%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets13.5%
Debt / equity0.00x
Current ratio6.98x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.14x
Accruals ratio37.9%
Payout ratio—
Capex / revenue0.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q3*2025-09-302025Q2*2025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue———$0$0$0$2.00M—
Cost of revenue———$0$0$0$1.99M—
Gross profit———$0$0$0$13,000—
R&D expense$0$0$1.59M$1.99M$1.15M$1.03M$2.21M$1.46M
SG&A expense$4.10M$2.77M$2.06M$3.68M$1.27M$1.46M$2.31M$2.13M
Operating income-$4.10M-$2.77M-$3.66M-$5.67M-$2.43M-$2.49M-$4.50M-$3.60M
Interest expense———————$0
Pretax income$28.28M$101.59M$49.44M$9.80M$59.45M$13.13M-$7.06M-$9.78M
Income tax$9.87M$23.43M$11.13M-$212,000$11.06M-$126,000$584,000$416,000
Net income$18.41M$78.16M$38.31M$10.01M$48.40M$13.29M-$7.64M-$10.23M
EBITDA-$4.07M-$2.73M-$3.63M-$5.64M-$2.40M-$2.46M-$4.47M-$3.56M
EPS (basic)0.441.900.94—1.160.32-0.19—
EPS (diluted)0.431.840.91—1.130.31-0.19—
Weighted avg. shares (diluted)43.02M42.50M41.97M—42.77M42.61M41.23M—
Balance sheet
Cash & equivalents$28.93M$15.24M$13.20M$45.95M$52.18M$15.80M$74.52M$54.42M
Short-term investments$583,000$846,000$4.96M$5.42M$4.96M$1.75M$3.69M$3.44M
Current assets$57.38M$53.41M$68.15M$133.27M$136.12M$99.03M$131.48M$143.22M
PP&E, net$506,000$532,000$561,000$586,000$614,000$645,000$671,000$698,000
Total assets$400.92M$369.64M$268.85M$230.86M$220.49M$161.68M$147.54M$155.28M
Current liabilities$9.45M$10.73M$10.56M$19.09M$6.12M$3.69M$5.49M$5.68M
Total liabilities$61.83M$52.17M$30.57M$31.12M$18.16M$8.10M$7.64M$9.93M
Shareholders' equity$339.09M$317.47M$238.28M$199.74M$203.28M$154.53M$140.81M$146.26M
Shares outstanding43.24M41.31M40.93M39.28M40.84M40.85M40.85M39.92M
Cash flow statement
Operating cash flow$426,000-$200,000-$2.92M-$466,000-$1.62M-$3.54M-$3.52M-$1.91M
Capital expenditure$4,000$2,000$5,000$2,000$0$4,000$3,000$11,000
Free cash flow$422,000-$202,000-$2.92M-$468,000-$1.62M-$3.54M-$3.52M-$1.92M
Investing cash flow$13.19M$4.31M-$19.49M-$1.68M$38.36M-$54.85M$23.62M$15.42M
Financing cash flow$40,000-$1.95M-$10.36M-$4.01M-$361,000——-$1.20M
Depreciation & amortization$30,000$31,000$30,000$30,000$31,000$30,000$30,000$31,000
Stock-based compensation$3.11M$1.39M$1.74M$2.28M$719,000$800,000$2.19M$1.23M
Dividends paid$57,000$78,000$10.36M—————
Share buybacks———$4.01M$361,000——$1.19M

Free plan shows the latest 8 periods; Pro shows all 69 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.